Solarea Bio Announces First Close of Series B Financing Round

Solarea Bio Announces First Close of Series B Financing Round

Source: 
BioSpace
snippet: 

Solarea Bio, a clinical stage biotechnology company based in Cambridge, MA developing food-derived microbial-based solutions to aid human health, announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.